Clinical Scorecard: Stability Assessment of Compounded Acetylcholine Chloride Intraocular Solution for Use in Intracoronary Provocative Vasospasm Testing
At a Glance
Category
Detail
Condition
Provocative coronary vasospasm testing
Key Mechanisms
Compounded acetylcholine chloride solution for intracoronary use
Target Population
Patients experiencing persistent angina without obstructive epicardial coronary artery disease
Care Setting
Invasive coronary function testing centers
Key Highlights
Compounded ACh solution met USP <797> stability criteria over 12 hours.
96.7% of initial ACh retained at 12 hours.
Subvisible particulate matter within USP <788> specifications.
Clear and colorless solution with a pH of 4.2.
Guideline-Based Recommendations
Diagnosis
Invasive guidewire-based hyperemic measurement of coronary flow reserve (CFR).
Intracoronary provocative coronary vasospasm testing with acetylcholine chloride.
Management
Utilization of compounded ACh for provocative coronary vasospasm testing.
Monitoring & Follow-up
Assessment of compounded ACh solution appearance, pH, particulate matter, concentration, and potency.
Risks
Potential for adverse events associated with off-label use of compounded ACh.
Patient & Prescribing Data
Patients with signs and symptoms of myocardial ischemia without obstructive CAD.
Clinical Best Practices
Follow USP <797> guidelines for compounding stability.
Conduct potency and stability testing in accredited laboratories.
Use compounded ACh within 12 hours of preparation.
